{"id":13365,"date":"2020-05-05T14:56:20","date_gmt":"2020-05-05T18:56:20","guid":{"rendered":"http:\/\/stateofthenation.co\/?p=13365"},"modified":"2020-05-05T14:58:36","modified_gmt":"2020-05-05T18:58:36","slug":"heres-a-list-of-dr-anthony-faucis-hiv-patents","status":"publish","type":"post","link":"http:\/\/stateofthenation.co\/?p=13365","title":{"rendered":"Here&#8217;s a list of Dr. Anthony Fauci&#8217;s HIV patents!"},"content":{"rendered":"<div class=\"wrapper\">\n<h1 class=\"heading-1\">Patents by Inventor Anthony S. Fauci<\/h1>\n<\/div>\n<div class=\"wrapper\">\n<div class=\"wrap\">\n<p>Anthony S. Fauci has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).<\/p>\n<\/div>\n<\/div>\n<p><!--more--><\/p>\n<div id=\"search-results\" class=\"wrapper\">\n<ul class=\"zebra list-no-styles has-no-padding has-negative-sides-30 has-no-bottom-margin\">\n<li class=\"has-padding-content-block-30 -zb\">\n<div class=\"head\">\n<h6 class=\"heading-6 has-no-margin\"><a href=\"https:\/\/patents.justia.com\/patent\/9896509\">Use of antagonists of the interaction between HIV GP120 and ?4?7 integrin<\/a><\/h6>\n<\/div>\n<div class=\"meta\">\n<div class=\"number\"><strong>Patent number: <\/strong>9896509<\/div>\n<div class=\"abstract\"><strong>Abstract: <\/strong>Methods are provided for the treatment of a HIV infection. The methods can include administering to a subject with an HIV infection a therapeutically effective amount of an agent that interferes with the interaction of gp120 and ?4 integrin, such as a ?4?1 or ?4?7 integrin antagonist, thereby treating the HIV infection. In several examples, the ?4 integrin antagonist is a monoclonal antibody that specifically binds to a ?4, ?1 or ?7 integrin subunit or a cyclic hexapeptide with the amino acid sequence of CWLDVC. Methods are also provided to reduce HIV replication or infection. The methods include contacting a cell with an effective amount of an agent that interferes with the interaction of gp120 and ?4 integrin, such as a ?4?1 or ?4?7 integrin antagonist. Moreover, methods are provided for determining if an agent is useful to treat HIV.<\/div>\n<div class=\"type\"><strong>Type: <\/strong>Grant<\/div>\n<div class=\"date-filed\"><strong>Filed: <\/strong>August 3, 2016<\/div>\n<div class=\"date-issued\"><strong>Date of Patent: <\/strong>February 20, 2018<\/div>\n<div class=\"assignees\"><strong>Assignee: <\/strong>The United States of America, as Represented by the Secretary, Department of Health and Human Services<\/div>\n<div class=\"inventors\"><strong>Inventors: <\/strong>James Arthos, Diana Goode, Claudia Cicala, Anthony S. Fauci<\/div>\n<\/div>\n<\/li>\n<li class=\"has-padding-content-block-30 -zb\">\n<div class=\"head\">\n<h6 class=\"heading-6 has-no-margin\"><a href=\"https:\/\/patents.justia.com\/patent\/20160333097\">USE OF ANTAGONISTS OF THE INTERACTION BETWEEN HIV GP120 AND A4B7 INTEGRIN<\/a><\/h6>\n<\/div>\n<div class=\"meta\">\n<div class=\"number\"><strong>Publication number: <\/strong>20160333097<\/div>\n<div class=\"abstract\"><strong>Abstract: <\/strong>Methods are provided for the treatment of a HIV infection. The methods can include administering to a subject with an HIV infection a therapeutically effective amount of an agent that interferes with the interaction of gp120 and ?4 integrin, such as a ?4?1 or ?4?7 integrin antagonist, thereby treating the HIV infection. In several examples, the ?4 integrin antagonist is a monoclonal antibody that specifically binds to a ?4, ?1 or ?7 integrin subunit or a cyclic hexapeptide with the amino acid sequence of CWLDVC. Methods are also provided to reduce HIV replication or infection. The methods include contacting a cell with an effective amount of an agent that interferes with the interaction of gp120 and ?4 integrin, such as a ?4?1 or ?4?7 integrin antagonist. Moreover, methods are provided for determining if an agent is useful to treat HIV.<\/div>\n<div class=\"type\"><strong>Type: <\/strong>Application<\/div>\n<div class=\"date-filed\"><strong>Filed: <\/strong>August 3, 2016<\/div>\n<div class=\"date-issued\"><strong>Publication date: <\/strong>November 17, 2016<\/div>\n<div class=\"assignees\"><strong>Applicant: <\/strong>THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Serv<\/div>\n<div class=\"inventors\"><strong>Inventors: <\/strong>James Arthos, Diana Goode, Claudia Cicala, Anthony S. Fauci<\/div>\n<\/div>\n<\/li>\n<li class=\"has-padding-content-block-30 -zb\">\n<div class=\"head\">\n<h6 class=\"heading-6 has-no-margin\"><a href=\"https:\/\/patents.justia.com\/patent\/9441041\">Use of antagonists of the interaction between HIV GP120 and ?4?7 integrin<\/a><\/h6>\n<\/div>\n<div class=\"meta\">\n<div class=\"number\"><strong>Patent number: <\/strong>9441041<\/div>\n<div class=\"abstract\"><strong>Abstract: <\/strong>Methods are provided for the treatment of a HIV infection. The methods can include administering to a subject with an HIV infection a therapeutically effective amount of an agent that interferes with the interaction of gp120 and ?4 integrin, such as a ?4?1 or ?4?7 integrin antagonist, thereby treating the HIV infection. In several examples, the ?4 integrin antagonist is a monoclonal antibody that specifically binds to a ?4, ?1 or ?7 integrin subunit or a cyclic hexapeptide with the amino acid sequence of CWLDVC. Methods are also provided to reduce HIV replication or infection. The methods include contacting a cell with an effective amount of an agent that interferes with the interaction of gp120 and ?4 integrin, such as a ?4?1 or ?4?7 integrin antagonist. Moreover, methods are provided for determining if an agent is useful to treat HIV.<\/div>\n<div class=\"type\"><strong>Type: <\/strong>Grant<\/div>\n<div class=\"date-filed\"><strong>Filed: <\/strong>September 21, 2015<\/div>\n<div class=\"date-issued\"><strong>Date of Patent: <\/strong>September 13, 2016<\/div>\n<div class=\"assignees\"><strong>Assignee: <\/strong>The United States of America, as Represented by the Secretary, Department of Health and Human Services<\/div>\n<div class=\"inventors\"><strong>Inventors: <\/strong>James Arthos, Diana Goode, Claudia Cicala, Anthony S. Fauci<\/div>\n<\/div>\n<\/li>\n<li class=\"has-padding-content-block-30 -zb\">\n<div class=\"head\">\n<h6 class=\"heading-6 has-no-margin\"><a href=\"https:\/\/patents.justia.com\/patent\/20160075786\">USE OF ANTAGONISTS OF THE INTERACTION BETWEEN HIV GP120 AND A4B7 INTEGRIN<\/a><\/h6>\n<\/div>\n<div class=\"meta\">\n<div class=\"number\"><strong>Publication number: <\/strong>20160075786<\/div>\n<div class=\"abstract\"><strong>Abstract: <\/strong>Methods are provided for the treatment of a HIV infection. The methods can include administering to a subject with an HIV infection a therapeutically effective amount of an agent that interferes with the interaction of gp120 and ?4 integrin, such as a ?4?1 or ?4?7 integrin antagonist, thereby treating the HIV infection. In several examples, the ?4 integrin antagonist is a monoclonal antibody that specifically binds to a ?4, ?1 or ?7 integrin subunit or a cyclic hexapeptide with the amino acid sequence of CWLDVC. Methods are also provided to reduce HIV replication or infection. The methods include contacting a cell with an effective amount of an agent that interferes with the interaction of gp120 and ?4 integrin, such as a ?4?1 or ?4?7 integrin antagonist. Moreover, methods are provided for determining if an agent is useful to treat HIV.<\/div>\n<div class=\"type\"><strong>Type: <\/strong>Application<\/div>\n<div class=\"date-filed\"><strong>Filed: <\/strong>September 21, 2015<\/div>\n<div class=\"date-issued\"><strong>Publication date: <\/strong>March 17, 2016<\/div>\n<div class=\"assignees\"><strong>Applicant: <\/strong>The United States of America, as Represented by the Secretary, Department of Health and Human Serv<\/div>\n<div class=\"inventors\"><strong>Inventors: <\/strong>James Arthos, Diana Goode, Claudia Cicala, Anthony S. Fauci<\/div>\n<\/div>\n<\/li>\n<li class=\"has-padding-content-block-30 -zb\">\n<div class=\"head\">\n<h6 class=\"heading-6 has-no-margin\"><a href=\"https:\/\/patents.justia.com\/patent\/20090285815\">IMMUNOCONJUGATES COMPRISING CD4 AND IMMUNOGLOBIN MOLECULES FOR THE TREATMENT OF HIV INFECTION<\/a><\/h6>\n<\/div>\n<div class=\"meta\">\n<div class=\"number\"><strong>Publication number: <\/strong>20090285815<\/div>\n<div class=\"abstract\"><strong>Abstract: <\/strong>Nucleic acids encoding recombinant CD4-fusion proteins are disclosed herein that include a CD4 polypeptide ligated at its C-terminus with a portion of an immunoglobulin comprising a hinge region and a constant domain of a mammalian immunoglobulin heavy chain. The portion of the IgG is fused at its C-terminus with a polypeptide comprising a tailpiece from the C terminus of the heavy chain of an IgA antibody or a tailpiece from a C terminus of the heavy chain of an IgM antibody. Also disclosed herein are methods for using these CD4-fusion proteins.<\/div>\n<div class=\"type\"><strong>Type: <\/strong>Application<\/div>\n<div class=\"date-filed\"><strong>Filed: <\/strong>March 21, 2008<\/div>\n<div class=\"date-issued\"><strong>Publication date: <\/strong>November 19, 2009<\/div>\n<div class=\"inventors\"><strong>Inventors: <\/strong>James Arthos, Claudia Cicala, Anthony S. Fauci<\/div>\n<\/div>\n<\/li>\n<li class=\"has-padding-content-block-30 -zb\">\n<div class=\"head\">\n<h6 class=\"heading-6 has-no-margin\"><a href=\"https:\/\/patents.justia.com\/patent\/7368114\">Fusion protein including of CD4<\/a><\/h6>\n<\/div>\n<div class=\"meta\">\n<div class=\"number\"><strong>Patent number: <\/strong>7368114<\/div>\n<div class=\"abstract\"><strong>Abstract: <\/strong>Novel recombinant polypeptides are disclosed herein that include a CD4 polypeptide ligated at its C-terminus with a portion of an immunoglobulin comprising a hinge region and a constant domain of a mammalian immunoglobulin heavy chain. The portion or the IgG is fused at its C-terminus with a polypeptide comprising a tailpiece from the C-terminus of the heavy chain of an IgA antibody ara tailpiece from a C-terminus of the heavy chain of an IgM antibody. Also disclosed herein are methods for using these CD4 fusion proteins.<\/div>\n<div class=\"type\"><strong>Type: <\/strong>Grant<\/div>\n<div class=\"date-filed\"><strong>Filed: <\/strong>October 24, 2002<\/div>\n<div class=\"date-issued\"><strong>Date of Patent: <\/strong>May 6, 2008<\/div>\n<div class=\"assignees\"><strong>Assignee: <\/strong>The United States of America as represented by the Department of Health and Human Services<\/div>\n<div class=\"inventors\"><strong>Inventors: <\/strong>James Arthos, Claudia Cicala, Anthony S. Fauci<\/div>\n<\/div>\n<\/li>\n<li class=\"has-padding-content-block-30 -zb\">\n<div class=\"head\">\n<h6 class=\"heading-6 has-no-margin\"><a href=\"https:\/\/patents.justia.com\/patent\/6911527\">HIV related peptides<\/a><\/h6>\n<\/div>\n<div class=\"meta\">\n<div class=\"number\"><strong>Patent number: <\/strong>6911527<\/div>\n<div class=\"abstract\"><strong>Abstract: <\/strong>This invention is the discovery of novel specific epitopes and antibodies associated with long term survival of HIV-1 infections. These epitopes and antibodies have use in preparing vaccines for preventing HIV-1 infection or for controlling progression to AIDS.<\/div>\n<div class=\"type\"><strong>Type: <\/strong>Grant<\/div>\n<div class=\"date-filed\"><strong>Filed: <\/strong>January 7, 2000<\/div>\n<div class=\"date-issued\"><strong>Date of Patent: <\/strong>June 28, 2005<\/div>\n<div class=\"assignees\"><strong>Assignee: <\/strong>The United States of America as represented by the Secretary of the Department of Health and Human Services<\/div>\n<div class=\"inventors\"><strong>Inventors: <\/strong>Giuseppe Scala, Xueni Chen, Oren J. Cohen, Anthony S. Fauci<\/div>\n<\/div>\n<\/li>\n<li class=\"has-padding-content-block-30 -zb\">\n<div class=\"head\">\n<h6 class=\"heading-6 has-no-margin\"><a href=\"https:\/\/patents.justia.com\/patent\/20040265306\">Efficient inhibition of hiv-1 viral entry through a novel fusion protein including of cd4<\/a><\/h6>\n<\/div>\n<div class=\"meta\">\n<div class=\"number\"><strong>Publication number: <\/strong>20040265306<\/div>\n<div class=\"abstract\"><strong>Abstract: <\/strong>Novel recombinant polypeptides are disclosed herein that include a CD4 polypeptide ligated at its C-terminus with a portion of an immunoglobulin comprising a hinge region and a constant domain of a mammalian immunoglobulin heavy chain. The portion of the IgG is fused at its C-terminus with a polypeptide comprising a tailpiece from the C-terminus of the heavy chain of an IgA antibody or a tailpiece from a C-terminus of the heavy chain of an IgM antibody. Also disclosed herein are methods for using these CD4-fusion proteins.<\/div>\n<div class=\"type\"><strong>Type: <\/strong>Application<\/div>\n<div class=\"date-filed\"><strong>Filed: <\/strong>July 27, 2004<\/div>\n<div class=\"date-issued\"><strong>Publication date: <\/strong>December 30, 2004<\/div>\n<div class=\"inventors\"><strong>Inventors: <\/strong>James Arthos, Claudia Cicala, Anthony S. Fauci<\/div>\n<\/div>\n<\/li>\n<li class=\"has-padding-content-block-30 -zb\">\n<div class=\"head\">\n<h6 class=\"heading-6 has-no-margin\"><a href=\"https:\/\/patents.justia.com\/patent\/20030180254\">Immunologic enhancement with intermittent interleukin-2 therapy<\/a><\/h6>\n<\/div>\n<div class=\"meta\">\n<div class=\"number\"><strong>Publication number: <\/strong>20030180254<\/div>\n<div class=\"abstract\"><strong>Abstract: <\/strong>A method for activating a mammalian immune system entails a series of IL-2 administrations that are effected intermittently over an extended period. Each administration of IL-2 is sufficient to allow spontaneous DNA synthesis in peripheral blood or lymph node cells of the patient to increase and peak, and each subsequent administration follows the preceding administration in the series by a period of time that is sufficient to allow IL-2 receptor expression in peripheral or lymph node blood of the patient to increase, peak and then decrease to 50% of peak value. This intermittent IL-2 therapy can be combined with another therapy which targets a specific disease state, such as an anti-retroviral therapy comprising, for example, the administration of AZT, ddI or interferon alpha. In addition, IL-2 administration can be employed to facilitate in situ transduction of T cells in the context of gene therapy.<\/div>\n<div class=\"type\"><strong>Type: <\/strong>Application<\/div>\n<div class=\"date-filed\"><strong>Filed: <\/strong>January 23, 2003<\/div>\n<div class=\"date-issued\"><strong>Publication date: <\/strong>September 25, 2003<\/div>\n<div class=\"assignees\"><strong>Applicant: <\/strong>The Govt. of the USA as represented by the Secretary of the Dept. of Health &amp; Human Services<\/div>\n<div class=\"inventors\"><strong>Inventors: <\/strong>H. Clifford Lane, Joseph A. Kovacs, Anthony S. Fauci<\/div>\n<\/div>\n<\/li>\n<li class=\"has-padding-content-block-30 -zb\">\n<div class=\"head\">\n<h6 class=\"heading-6 has-no-margin\"><a href=\"https:\/\/patents.justia.com\/patent\/6548055\">Immunologic enhancement with intermittent interleukin-2 therapy<\/a><\/h6>\n<\/div>\n<div class=\"meta\">\n<div class=\"number\"><strong>Patent number: <\/strong>6548055<\/div>\n<div class=\"abstract\"><strong>Abstract: <\/strong>A method for activating a mammalian immune system entails a series of IL-2 administrations that are effected intermittently over an extended period. Each administration of IL-2 is sufficient to allow spontaneous DNA synthesis in peripheral blood or lymph node cells of the patient to increase and peak, and each subsequent administration follows the preceding administration in the series by a period of time that is sufficient to allow IL-2 receptor expression in peripheral or lymph node blood of the patient to increase, peak and then decrease to 50% of peak value. This intermittent IL-2 therapy can be combined with another therapy which targets a specific disease state, such as an anti-retroviral therapy comprising, for example, the administration of AZT, ddI or interferon alpha. In addition, IL-2 administration can be employed to facilitate in situ transduction of T cells in the context of gene therapy.<\/div>\n<div class=\"type\"><strong>Type: <\/strong>Grant<\/div>\n<div class=\"date-filed\"><strong>Filed: <\/strong>August 9, 2000<\/div>\n<div class=\"date-issued\"><strong>Date of Patent: <\/strong>April 15, 2003<\/div>\n<div class=\"assignees\"><strong>Assignee: <\/strong>The United States of America as represented by the Department of Health and Human Services<\/div>\n<div class=\"inventors\"><strong>Inventors: <\/strong>H. Clifford Lane, Joseph A. Kovacs, Anthony S. Fauci<\/div>\n<\/div>\n<\/li>\n<li class=\"has-padding-content-block-30 -zb\">\n<div class=\"head\">\n<h6 class=\"heading-6 has-no-margin\"><a href=\"https:\/\/patents.justia.com\/patent\/6190656\">Immunologic enhancement with intermittent interleukin-2 therapy<\/a><\/h6>\n<\/div>\n<div class=\"meta\">\n<div class=\"number\"><strong>Patent number: <\/strong>6190656<\/div>\n<div class=\"abstract\"><strong>Abstract: <\/strong>A method for activating a mammalian immune system entails a series of IL-2 administrations that are effected intermittently over an extended period. Each administration of IL-2 is sufficient to allow spontaneous DNA synthesis in peripheral blood or lymph node cells of the patient to increase and peak, and each subsequent administration follows the preceding administration in the series by a period of time that is sufficient to allow IL-2 receptor expression in peripheral or lymph node blood of the patient to increase, peak and then decrease to 50% of peak value. This intermittent IL-2 therapy can be combined with another therapy which targets a specific disease state, such as an anti-retroviral therapy comprising, for example, the administration of AZT, ddI or interferon alpha. In addition, IL-2 administration can be employed to facilitate in situ transduction of T cells in the context of gene therapy.<\/div>\n<div class=\"type\"><strong>Type: <\/strong>Grant<\/div>\n<div class=\"date-filed\"><strong>Filed: <\/strong>September 2, 1997<\/div>\n<div class=\"date-issued\"><strong>Date of Patent: <\/strong>February 20, 2001<\/div>\n<div class=\"assignees\"><strong>Assignee: <\/strong>The United States of America as represented by the Department of Health and Human Services<\/div>\n<div class=\"inventors\"><strong>Inventors: <\/strong>H. Clifford Lane, Joseph A. Kovacs, Anthony S. Fauci<\/div>\n<\/div>\n<\/li>\n<li class=\"has-padding-content-block-30 -zb\">\n<div class=\"head\">\n<h6 class=\"heading-6 has-no-margin\"><a href=\"https:\/\/patents.justia.com\/patent\/5696079\">Immunologic enhancement with intermittent interleukin-2 therapy<\/a><\/h6>\n<\/div>\n<div class=\"meta\">\n<div class=\"number\"><strong>Patent number: <\/strong>5696079<\/div>\n<div class=\"abstract\"><strong>Abstract: <\/strong>A method for activating a mammalian immune system entails a series of IL-2 administrations that are effected intermittently over an extended period. Each administration of IL-2 is sufficient to allow spontaneous DNA synthesis in peripheral blood or lymph node cells of the patient to increase and peak, and each subsequent administration follows the preceding administration in the series by a period of time that is sufficient to allow IL-2 receptor expression in peripheral or lymph node blood of the patient to increase, peak and then decrease to 50% of peak value. This intermittent IL-2 therapy can be combined with another therapy which targets a specific disease state, such as an anti-retroviral therapy comprising, for example, the administration of AZT, ddI or interferon alpha. In addition, IL-2 administration can be employed to facilitate in situ transduction of T cells in the context of gene therapy.<\/div>\n<div class=\"type\"><strong>Type: <\/strong>Grant<\/div>\n<div class=\"date-filed\"><strong>Filed: <\/strong>May 26, 1995<\/div>\n<div class=\"date-issued\"><strong>Date of Patent: <\/strong>December 9, 1997<\/div>\n<div class=\"assignees\"><strong>Assignee: <\/strong>The United States of America as represented by the Department of Health and Human Services<\/div>\n<div class=\"inventors\"><strong>Inventors: <\/strong>H. Clifford Lane, Joseph A. Kovacs, Anthony S. Fauci<\/div>\n<\/div>\n<\/li>\n<\/ul>\n<\/div>\n<p>___<br \/>\n<a href=\"https:\/\/patents.justia.com\/inventor\/anthony-s-fauci\">https:\/\/patents.justia.com\/inventor\/anthony-s-fauci<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Patents by Inventor Anthony S. Fauci Anthony S. Fauci has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent &hellip; <a href=\"http:\/\/stateofthenation.co\/?p=13365\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-13365","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"http:\/\/stateofthenation.co\/index.php?rest_route=\/wp\/v2\/posts\/13365","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/stateofthenation.co\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/stateofthenation.co\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/stateofthenation.co\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/stateofthenation.co\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=13365"}],"version-history":[{"count":0,"href":"http:\/\/stateofthenation.co\/index.php?rest_route=\/wp\/v2\/posts\/13365\/revisions"}],"wp:attachment":[{"href":"http:\/\/stateofthenation.co\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=13365"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/stateofthenation.co\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=13365"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/stateofthenation.co\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=13365"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}